A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
NCT ID: NCT06267001
Last Updated: 2025-11-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
56 participants
INTERVENTIONAL
2024-03-21
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
NCT04832854
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04619797
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT04513925
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
NCT04256421
A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer
NCT04267237
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atezolizumab + Tiragolumab
Participants will receive atezolizumab and tiragolumab intravenously (IV).
Atezolizumab
Atezolizumab will be administered IV.
Tiragolumab
Tiragolumab will be administered IV.
Atezolizumab + Placebo
Participants will receive atezolizumab and placebo IV.
Atezolizumab
Atezolizumab will be administered IV.
Placebo
Placebo will be administered IV.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atezolizumab
Atezolizumab will be administered IV.
Tiragolumab
Tiragolumab will be administered IV.
Placebo
Placebo will be administered IV.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histological or cytological diagnosis of Stage IIB, IIIA, and select IIIB NSCLC of either non-squamous or squamous histology
* Participants must have had complete resection of NSCLC
* Participants must have received between one to four cycles of adjuvant histology-based platinum doublet chemotherapy
* Participants must have recovered adequately from surgery and from adjuvant chemotherapy
* Tumor cell PD-L1 expression at \>/= 1%
* Adequate hematologic and end-organ function.
Exclusion Criteria
* Any evidence of residual disease or disease recurrence following surgical resection of NSCLC, or during or following adjuvant chemotherapy
* NSCLC known to have mutation in the epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) fusion oncogene
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro Oncologico Korben
Ciudad Autonoma Buenos Aires, , Argentina
Sunshine Coast University Hospital
Birtinya, Queensland, Australia
Monash Health
Clayton, Victoria, Australia
Crio - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil
Nucleo de Oncologia da Bahia - NOB
Salvador, Bahia, Estado de Bahia, Brazil
Hospital de Clínicas de Passo Fundo
Passo Fundo, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Hospital A. C. Camargo
São Paulo, São Paulo, Brazil
Changzhou First People's Hospital
Changzhou, , China
Guangdong General Hospital
Guangzhou, , China
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, , China
Shandong Cancer Hospital
Jinan, , China
Yunnan Cancer Hospital
Kunming, , China
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
Nanjing, , China
Ningbo No.2 Hospital
Ningbo, , China
Liaoning Provincial Cancer Hospital
Shengyang, , China
Tianjin Cancer Hospital
Tianjin, , China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, , China
Zhejiang Cancer Hospital
Zhejiang, , China
Ospedale P. Pederzoli Casa di cura Privata
Peschiera Del Garda (VR), Veneto, Italy
Hiroshima University Hospital
Hiroshima, , Japan
Kindai University Hospital
Osaka, , Japan
Instytut Gruzlicy I Chorob Pluc
Warsaw, , Poland
Pusan National University Hospital
Busan, , South Korea
Kyungpook National University Chilgok Hospital
Daegu, , South Korea
St. Vincent's Hospital
Gyeonggi-do, , South Korea
Pusan National University Yangsan Hospital
Gyeongsangnam-do, , South Korea
Seoul National University Bundang Hospital
Seongnam-si, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Korea University Guro Hospital
Seoul, , South Korea
E-DA Hospital
Kaohsiung City, , Taiwan
Taichung Veterans General Hospital
Taichung, , Taiwan
National Taiwan University Cancer Center
Zhongzheng Dist., , Taiwan
Vajira Hospital
Bangkok, , Thailand
Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji
Bakirkoy / Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-506696-10-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
GO45006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.